1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2

Patent metadata

Field	Value
Publication number	US-9815813-B2
Application number	US-201515110504-A
Country	US
Kind code	B2
Filing date	Jan 16, 2015
Priority date	Jan 17, 2014
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The present invention relates to compounds of formula I:

in which Y 1 , Y 2 , Y 3 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

First claim

We claim:

1. A compound of Formula I:

in which:
Y 1 is selected from CH and N;
Y 2 is selected from CR 6 and N;
Y 3 is CR 7 R 8 ;
R 1 is —XR 1a ; wherein
R 1a is selected from C 6-10 aryl, and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S;
wherein said aryl or heteroaryl of R 1a is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, C 1-4 alkoxy, hydroxy-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkyl, amino-substituted-C 1-4 alkyl, —C(O)OR 10 , —NHC(O)R 10 and tetrazolyl;
wherein R 10 is selected from hydrogen, halo-substituted-C 1-4 alkyl, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;

and
X is selected from S(O) m ;
wherein m is selected from 0, 1 and 2;

R 2a and R 2b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 3a and R 3b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 4a and R 4b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 5a and R 5b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, —S(O) 1-2 R 6a , —C(S)R 6a , —C(O)NR 6a R 6b , —C(NH)NR 6a R 6b and —NR 6a C(O)R 6b ; wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;
R 7 is selected from hydrogen, C 1-4 alkyl, halo, hydroxy, hydroxy-substituted-C 1-4 alkyl, C 3-6 cycloalkyl, phenyl and a 5 to 6 membered heteroaryl containing up to 3 heteroatoms selected from O, S and N; and
R 8 is selected from amino, amino-substituted-C 1-4 alkyl and methyl-amino;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of Formula Ia:

in which:
n is selected from 1, 2, 3, 4 and 5;
Y 1 is selected from CH and N;
Y 2 is selected from CR 6 and N;
R 4a is selected from hydrogen and hydroxy;
R 6 is selected from hydrogen, halo, methyl and —C(O)NR 6a R 6b , wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;
R 7 is selected from hydrogen, methyl, halo, hydroxy, hydroxy-methyl, phenyl, pyridinyl, pyrazinyl and thiazolyl;
R 8 is selected from amino, amino-methyl, 1-aminoethyl and methyl-amino;
R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, halo-substituted-C 1-4 alkyl, C 1-4 alkoxy, —C(O)OR 10 , —NHC(O)R 10 and tetrazolyl;
R 10 is selected from hydrogen, halo-substituted-C 1-4 alkyl, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , or the pharmaceutically acceptable salt thereof, selected from:

4. The compound of claim 1 of Formula Ic:

in which:
n is selected from 1, 2, 3 and 4;
Y 1 is selected from CH and N;
Y 2 is selected from CR 6 and N;
R 4a is selected from hydrogen and hydroxy;
R 6 is selected from hydrogen, halo, methyl and —C(O)NR 6a R 6b , wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;
R 7 is selected from hydrogen, methyl, halo, hydroxy, hydroxy-methyl, phenyl, pyridinyl, pyrazinyl and thiazolyl;
R 8 is selected from amino, amino-methyl, 1-aminoethyl and methyl-amino;
R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, C 1-4 alkoxy, halo-substituted-C 1-4 alkyl, C 1-4 alkoxy, —C(O)OR 10 , —NHC(O)R 10 and tetrazolyl;
R 10 is selected from hydrogen, halo-substituted-C 1-4 alkyl, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , or the pharmaceutically acceptable salt thereof, selected from:

6. The compound of claim 1 of Formula Id:

in which:
n is selected from 1, 2, 3 and 4;
Y 1 is selected from CH and N;
Y 2 is selected from CR 6 and N;
R 4a is selected from hydrogen and hydroxy;
R 6 is selected from hydrogen, halo, methyl and —C(O)NR 6a R 6b , wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;
R 7 is selected from methyl, ethyl, propyl, hydroxy, halo, hydroxy-methyl, phenyl, pyridinyl, pyrazinyl and thiazolyl;
R 8 is selected from amino, amino-methyl, 1-aminoethyl and methyl-amino;
R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, C 1-4 alkoxy, halo-substituted-C C 1-4 alkoxy, —C(O)OR 10 , —NHC(O)R 10 and tetrazolyl;
R 10 is selected from hydrogen, halo-substituted-C 1-4 alkyl, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , or the pharmaceutically acceptable salt thereof, selected from:

8. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

Assignees

• Chen Zhuoliang
• Dore Michael
• Fortanet Jorge Garcia
• Karki Rajesh
• Kato Mitsunori
• Lamarche Matthew J
• Perez Lawrence Blas
• Williams Sarah
• Sendzik Martin
• Novartis Ag

Inventors

• Chen Zhuoliang
• Dore Michael
• Fortanet Jorge Garcia
• Karki Rajesh
• Kato Mitsunori
• Lamarche Matthew J
• Perez Lawrence Blas
• Williams Sarah
• Sendzik Martin

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07D249/14

  Nitrogen atoms · CPC title